Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828535 | 0.83 | YTHDC1 (0.40) | LMNAALDH3A1CA1CA2CXCL8 | |
| SCHEMBL29426179 | 0.82 | ALDH1A1 (0.50) | LMNAALDH3A1CXCL8GAANOD2 | |
| SCHEMBL22587454 | 0.81 | LATS1 (0.44) | LMNAALDH3A1CA1CA2CXCL8 | |
| SCHEMBL15408335 | 0.81 | LMNA (0.41) | LMNAALDH3A1CA1CA2CXCL8 | |
| SCHEMBL22587478 | 0.80 | GPR6 (0.41) | LMNANOD2NOD1PKMMAPT | |
| SCHEMBL22587498 | 0.80 | KMT2A (0.42) | LMNAALDH3A1CA1CA2GAA | |
| SCHEMBL29426251 | 0.80 | KMT2A (0.42) | LMNAALDH3A1CA1CA2GAA | |
| SCHEMBL29426266 | 0.79 | YTHDC1 (0.39) | LMNAALDH3A1PPARGPPARDL3MBTL1 | |
| SCHEMBL22587421 | 0.78 | HTR6 (0.43) | LMNANOD2NOD1TSHRALDH1A1 | |
| SCHEMBL29426264 | 0.78 | HTR6 (0.41) | LMNANOD2NOD1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-114127063-B | Pyrimidine five-membered heterocyclic compounds and application thereof as mutant IDH2 inhibitor | 上海仕谱生物科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20220204509-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | Epitas Biosciences (shanghai) Co., Ltd. (CN) | 2022-06-30 | — | — | US | disclosed |
| EP-3967691-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | Epitas Biosciences (Shanghai) Co., Ltd. (CN) | 2022-03-16 | — | — | EP | disclosed |
| CN-114127063-A | Pyrimido five-membered heterocyclic compounds and application thereof as mutant IDH2 inhibitor | 上海仕谱生物科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| WO-2010038060-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | ADORA2A, ADORA1, ADORA3 | LMNA 2415/4885ALDH3A1 348/4885CA1 4010/4885 |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | ADORA2A, ADORA1, ADORA3 | LMNA 2415/4885ALDH3A1 348/4885CA1 4010/4885 |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | LMNA 2415/4885ALDH3A1 348/4885CA1 4010/4885 |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | JAK2, JAK1, JAK3 | LMNA 3361/4885ALDH3A1 2787/4885CA1 4737/4885 |
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | LMNA 2415/4885ALDH3A1 348/4885CA1 4010/4885 |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | LMNA 4161/4885ALDH3A1 1345/4885CA1 4866/4885 |
| US-20220204509-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | IDH2, IDH1, IDH3A | LMNA 3540/4885ALDH3A1 55/4885CA1 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.